Viemed Healthcare (NASDAQ:VMD) President Michael Moore Sells 31,570 Shares

Viemed Healthcare, Inc. (NASDAQ:VMD) President Michael Moore sold 31,570 shares of Viemed Healthcare stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $9.42, for a total value of $297,389.40. Following the completion of the sale, the president owned 1,691,044 shares of the company’s stock, valued at approximately $15,929,634.48. The trade was a 1.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Michael Moore also recently made the following trade(s):

• On Friday, March 20th, Michael Moore sold 65,000 shares of Viemed Healthcare stock. The shares were sold at an average price of $8.77, for a total value of $570,050.00.
• On Thursday, March 19th, Michael Moore sold 40,232 shares of Viemed Healthcare stock. The shares were sold at an average price of $9.21, for a total value of $370,536.72.

Viemed Healthcare Stock Down 5.5%

Shares of NASDAQ VMD traded down $0.51 during midday trading on Friday, hitting $8.71. 703,686 shares of the stock traded hands, compared to its average volume of 245,033. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.06 and a current ratio of 1.18. Viemed Healthcare, Inc. has a one year low of $5.93 and a one year high of $10.06. The business has a 50 day moving average price of $8.30 and a two-hundred day moving average price of $7.37. The company has a market cap of $336.21 million, a PE ratio of 23.54 and a beta of 1.23.

Viemed Healthcare (NASDAQ:VMD) last released its quarterly earnings data on Wednesday, March 4th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.02. Viemed Healthcare had a net margin of 5.53% and a return on equity of 10.72%. The firm had revenue of $76.18 million for the quarter, compared to the consensus estimate of $77.70 million.

Wall Street Analyst Weigh In

Several brokerages have recently commented on VMD. Wall Street Zen raised Viemed Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “hold (c)” rating on shares of Viemed Healthcare in a research report on Monday, December 29th. Finally, Zacks Research raised shares of Viemed Healthcare to a “hold” rating in a report on Thursday, January 8th. Two investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Viemed Healthcare has a consensus rating of “Hold”.

Institutional Investors Weigh In On Viemed Healthcare

Several large investors have recently made changes to their positions in VMD. AQR Capital Management LLC purchased a new position in shares of Viemed Healthcare in the 1st quarter worth about $90,000. Jane Street Group LLC purchased a new position in Viemed Healthcare in the first quarter valued at about $394,000. Geode Capital Management LLC grew its position in shares of Viemed Healthcare by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 798,515 shares of the company’s stock valued at $5,519,000 after acquiring an additional 15,353 shares during the period. Intech Investment Management LLC grew its position in shares of Viemed Healthcare by 14.4% during the 2nd quarter. Intech Investment Management LLC now owns 18,612 shares of the company’s stock valued at $129,000 after acquiring an additional 2,349 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Viemed Healthcare by 3.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 174,551 shares of the company’s stock worth $1,206,000 after purchasing an additional 5,099 shares during the last quarter. 74.24% of the stock is owned by hedge funds and other institutional investors.

About Viemed Healthcare

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.